BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare CNS: Amyotrophic Lateral Sclerosis (ALS) Market Spotlight

November 29, 2021

Amyotrophic lateral sclerosis (ALS) is a fatal late-onset neurodegenerative disorder characterized by progressive muscular paralysis. It leads to damage of the upper and lower motor neurons present in the corticospinal tracts, brainstem, primary motor cortex, and spinal cord. The first onset of symptoms is generally seen in patients aged 50–65 years. Common symptoms reported by patients with ALS include muscle twitching, weakness, and cramping, which subsequently lead to muscle impairment. Furthermore, patients in the final stages of ALS will develop symptoms of dysphagia and dyspnea. 

This Datamonitor Healthcare report contains a Market Spotlight module.

Indications Covered: Amyotrophic Lateral Sclerosis (ALS)
Back to the top Back to the top